<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Research Services Division</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/85630540-731E-4970-B864-9B64110A77A7"><gtr:id>85630540-731E-4970-B864-9B64110A77A7</gtr:id><gtr:firstName>Gordon</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A9032356-5E03-4D00-BF4A-1E00ED5A1469"><gtr:id>A9032356-5E03-4D00-BF4A-1E00ED5A1469</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Charnock-Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100221"><gtr:id>9072D213-1D1A-493E-99F1-AC245B0ADC40</gtr:id><gtr:title>The identification of novel biomarkers for the small for gestational age human fetus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100221</gtr:grantReference><gtr:abstractText>Babies who grow poorly in the womb (called small for gestational age [SGA]) are at increased risk of a number of adverse outcomes, including stillbirth. Screening pregnant women in an attempt to detect SGA babies has the potential to reduce the number of these adverse outcomes, in particular stillbirth, which accounts for the death of about 4000 babies per annum in the UK. Current practice in the UK in screening the general population for SGA babies is confined to measuring the woman?s bump (technically called ?symphysis-fundal height?) with a tape measure. However, this approach is known not to be particularly good at picking up small babies. The approach to SGA is very crude in comparison to the approach to screening for Down?s syndrome babies in pregnancy. Down?s syndrome screening utilises a combination of scan and blood markers and now detects 90% of cases with only a small proportion of women requiring further tests. There are also a number of scan and blood markers for SGA babies, but none of these is good enough on its own to predict them. We believe that it will be possible to identify novel markers which may be more effective than existing blood tests. In fact, relatively few studies have systematically looked for better markers and most of the existing blood tests which could help predict SGA were discovered by chance. We have access to scan information, blood samples and placental (afterbirth) samples from a large scale study of unselected women in their first pregnancy ( 2800 women and on target to recruit 5000). The overarching aim of the present application is to see if we can find better markers in the mother?s blood of poorly grown babies. Specifically, we plan to determine the key differences in the genes expressed in the placenta of SGA babies and matched controls. We then aim to see if the proteins encoded by these genes are found at different concentrations in the placenta and in the mother?s blood. Finally, we aim to determine whether information about the levels of these proteins improves the prediction of SGA babies. The end result will be a predictive tool (algorithm) to detect small babies. We could then design trials of the tool to see if it improved outcome. The ultimate aim is to make care of pregnant women more effective and to reduce the number of babies lost to stillbirth.</gtr:abstractText><gtr:technicalSummary>Small for gestational age infants (SGA) are at increased risk of a number of adverse outcomes. Screening for SGA has the potential to reduce the number of adverse outcomes, in particular population rates of stillbirth, which account for the death of about 4000 babies per annum in the UK. The 2008 NICE Guideline on Antenatal Care identified improving detection of SGA infants as one of 5 major research priorities. The current exemplar of pregnancy screening is Down?s syndrome, which utilises a combination of ultrasonic and biochemical markers and now detects 90% of cases for a less than 5% false positive rate. We have previously reported associations between a range of ultrasonic and biochemical measurements and the risk of delivery of a SGA infant, but none of these has the discrimination to provide clinically useful prediction. We have hypothesised that this may be achieved by combined ultrasonic and biochemical assessment of the fetus and placenta. The current project will use the Pregnancy Outcome Prediction study, a prospective cohort study of unselected nulliparous women. The study combines serial ultrasonic fetal biometry and utero-placental Doppler and maternal blood sampling at 12, 20, 28 and 36 weeks; and systematic sampling of the placenta following delivery. The study has already recruited 2800 women, has placental samples stored from 1900 women and continues to recruit approximately 100 women per month. The design of the study allows optimal phenotyping of cases of SGA (using both Doppler and growth velocity) and comparison with controls matched in relation to key maternal and obstetric characteristics. Preliminary analysis of the ultrasonic data indicated that an algorithm based on scan data alone only picked up about half of SGA infants for a 10% screen positive rate. The aims of the present study are (1) to compare expression gene array of placental samples from infants with different phenotypes of SGA at term and to compare them with matched controls, (2) to validate variation in placental levels of candidate biomarkers using qRT-PCR, Western blot and immunohistochemistry in a separate series of cases and matched controls, (3) to use a case cohort approach to compare maternal serum levels of candidate biomarkers and assess their screening performance in combination with serial ultrasound. The ultimate aim is to generate an algorithm for the identification of pathologically SGA infants that might ultimately be tested in a randomised controlled trial of screening the general population.</gtr:technicalSummary><gtr:fund><gtr:end>2015-08-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>418100</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Clinical Research Agreement with Roche</gtr:description><gtr:id>7E185704-527E-471E-8AF3-28548A4EBEC4</gtr:id><gtr:impact>Prediction of preeclampsia using the sFLT-1:PIGF ratio: a prospective cohort study of unselected nulliparous women (http://doi:10.1016/j.preghy.2016.08.047)
Screening for late fetal growth restriction using ultrasound and the sFlt-1:PlGF ratio
Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women</gtr:impact><gtr:partnerContribution>Roche provided a loan of a clinical grade immunoassay system (Cobas e411) and reagents to analyse 5 placental biomarkers (PAPP-A, AFP, hCG, sFlt-1 &amp;amp; PlGF) in all ~16,000 samples. They also provided training of our staff, and a maintenance contract plus technical support. The valuation of &amp;pound;596142.00 was costed by Roche.</gtr:partnerContribution><gtr:piContribution>We had conducted a prospective cohort study of unselected nulliparous women (the Pregnancy Outcome Prediction study). We collected ~16,000 serum and plasma samples from ~4,500 pregnant women, and have detailed clinical information on exposures and adverse outcomes. A team of technicians manage the biobank. This was funded by the NIHR Cambridge Comprehensive Biomedical Research Centre, and management of the biobank and sample analysis is support by an MRC project grant, G1100221 (The identification of novel biomarkers for the small for gestational age human fetus). The collaboration has allowed us to expand substantially the aims outlined in that grant to measure a series of placental biomarkers in pregnancies complicated by fetal growth restriction. With the collaboration, we are now able to measure placental biomarkers in the entire cohort, rather than perform a case control or case cohort study. We have completed approximately 80,000 ELISAs through the combined effort of the MRC Grant and the first outputs were published in early 2017.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>5th International FGM Conference, Toronto, Canada</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>871515B3-2E16-4133-9D56-CF864AE1FA4D</gtr:id><gtr:impact>Invited to be a panel member for the discussion entitled 'Session Two Panel Discussion and Q&amp;amp;A' 19 November 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.fetalgrowth2016.ca/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Maternity Hospital / Queens University Perinatal Annual Lecture, Belfast, Ireland</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E410E8B1-0CF7-4FE4-BE63-D6448FADB05C</gtr:id><gtr:impact>Professor Smith was personally invited by the organisers of the Perinatal Annual Lecture at Royal Maternity Hospital / Queens University to be their speaker for 2015. The lecture is followed by a dinner. It took place 1 October in Belfast, Ireland. All associated travel costs were covered by the organisers. The title of the talk was 'Screening for fetal growth restriction'.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5th International FGM Conference, Toronto, Canada</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>88B3F1FD-49C2-4541-B99C-DBBD897112FD</gtr:id><gtr:impact>Invited to be a panel member for the discussion entitled 'Quiz and Inter-active Panel Discussion' 19 November 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.fetalgrowth2016.ca/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCOG Annual Academic Award presentation, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95AB9DA5-6A79-402F-AD48-E3B052B99734</gtr:id><gtr:impact>Professor Gordon Smith invited to give a presentation as part of the award ceremony where he was presented with the RCOG Annual Academic Award. Title 'Screening for adverse pregnancy outcome: the future' given 2 March</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh Obstetrical Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>653BEDD8-C416-48DA-9FB1-ECBC318B451F</gtr:id><gtr:impact>Professor Gordon Smith was invited by the Senior Secretary of the Edinburgh Obstetrical Society to speak at their monthly meeting which will take place 9 March 2016. The title of his talk will be 'Screening for adverse pregnancy outcomes'. All travel costs associated with this invitation will be covered.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5th International FGM Conference, Toronto, Canada</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>438C71E6-2FE1-4C33-9682-E6C875FD4410</gtr:id><gtr:impact>Invited to be a panel member, title 'Screening for IUGR Panel Discussion and Q&amp;amp;A' 18 November 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.fetalgrowth2016.ca/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>O&amp;G Clinical Seminar Series, Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3D22307-F177-4ECD-A4B2-B919FB115E18</gtr:id><gtr:impact>Invited to present as part of the seminar series. Title 'Understanding the relationship between advanced maternal age and pregnancy outcome'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BMFMS 18th Annual Conference, Birmingham, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9FEF1273-1729-4C36-AEAE-3140E85644A4</gtr:id><gtr:impact>Accepted abstract title 'Prenatal prediction of the risk of emergency cesarean delivery and associated morbidity in low risk nulliparous women at term'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bmfms.org.uk/Annual-conference/BMFMS-2016/c-1-32-186</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5th International FGM Conference, Toronto, Canada</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AB786540-F02C-416E-8685-4F36F252B82C</gtr:id><gtr:impact>Invited to take part in the panel discussion entitled 'Convergence on Current IUGR Guidelines Panel Discussion and Q&amp;amp;A' 18 November 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.fetalgrowth2016.ca/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CTR Placental Biology Course, Cambridge, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3F1BD826-21ED-440A-BD5C-2AE70EC03915</gtr:id><gtr:impact>Invited to present at the annual Centre for Trophoblast Research Placental Biology Course, Cambridge University. Title 'Clinical Study Design'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.trophoblast.cam.ac.uk/events/ctr-placenta-2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Obstetrical &amp; Gynaecological Society (GOGS), Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8B977BE9-BDE1-429A-A1E7-D9167BA72830</gtr:id><gtr:impact>Invited to present at the GOGS regular evening seminar. Title 'Prevention of stillbirth' presented 15 February.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.gogs.org.uk/meetings.htm</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regional PG Meeting, O&amp;G, School of Medicine, University of Nottingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5FE8A098-7B29-4EA1-AFD8-B2723D0C33B5</gtr:id><gtr:impact>Invited to present at the meeting. Title 'Mode of delivery for twins at term: a level playing field of evidence'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Fetal Medicine Symposium, Wales</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>71F2830A-5B34-4138-A22C-8B9B409EC721</gtr:id><gtr:impact>Invited to speak at the symposium, title 'Beyond the measuring tape - screening for IUGR'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture and visit to Illumina, Redwood City, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>10767DE7-82B3-4D7E-B178-555006F730F5</gtr:id><gtr:impact>Invited to visit and present a lecture at Illumina. Research collaboration discussions also took place.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scottish Government Stillbirth Conference, Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>981DC69B-C934-4B92-AA06-E3EFA86E78CA</gtr:id><gtr:impact>Invited to be a member of the panel 'Induction of Labour at 39 weeks, what harm can it do? Speaking 'for'.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.sad.scot.nhs.uk/support-around-death-news/2017/january/edinburgh-international-conference-centre/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>O&amp;G Grand Round, School of Medicine, Yale University, Connecticut, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>92E5865C-9F16-45C6-B074-A085EC61E86C</gtr:id><gtr:impact>Invited to present at the Grand Round, Yale University 13 October 2016. All travel and related expenses covered by Yale University.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EAOGS Autumn meeting, Cambridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>91E01796-F75B-431E-A2EF-9F5A57849932</gtr:id><gtr:impact>Professor Smith was personally invited to present as part of the EAOGS Autumn meeting 17 October in Cambridge. The title of his talk was 'The future of screening for fetal growth restriction'.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20916</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Research Capability Funding</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Cambridge University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>3819151622</gtr:fundingRef><gtr:id>BFA24509-32CB-4317-8C49-A13F7861858C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Returning Carers Scheme 2014/15: third round</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>83BEC55A-5BC5-4658-B5C1-7AD777DFFF29</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Wrote chapter for the Chief Medical Officer's Annual Report 2014 on Antenatal Screening</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AB4D0788-1ED4-4867-9374-2463FDCEFC90</gtr:id><gtr:type>Gave evidence to a government review</gtr:type><gtr:url>https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/484383/cmo-report-2014.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F674A52-06DE-4207-8D4A-DD704CF31616"><gtr:id>2F674A52-06DE-4207-8D4A-DD704CF31616</gtr:id><gtr:title>Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9964cb4ec266df328a7faeee5273d37c"><gtr:id>9964cb4ec266df328a7faeee5273d37c</gtr:id><gtr:otherNames>Cleaton MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FD9D366-966F-43B6-B035-CD67306B7291"><gtr:id>6FD9D366-966F-43B6-B035-CD67306B7291</gtr:id><gtr:title>Gender Imbalance Confounds Meta-Analysis of Pre-Eclampsia Microarray Studies of the Placental Transcriptome</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b261e3b7fd63ff5c4d7a58f8b5f637a"><gtr:id>1b261e3b7fd63ff5c4d7a58f8b5f637a</gtr:id><gtr:otherNames>Dopierala J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39A6C799-694D-438F-AEB4-1DA1C7512C7F"><gtr:id>39A6C799-694D-438F-AEB4-1DA1C7512C7F</gtr:id><gtr:title>Sex-Specific Differences in Placental Methylation That Are Associated with Transcript Abundance</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b29bc4f01a1e5d64d60d2682a53ad95f"><gtr:id>b29bc4f01a1e5d64d60d2682a53ad95f</gtr:id><gtr:otherNames>Johnson MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51284BE8-F1AE-41C6-99D8-8994AC7C0932"><gtr:id>51284BE8-F1AE-41C6-99D8-8994AC7C0932</gtr:id><gtr:title>miRNAs Associated with Small for Gestational Age in Placenta and Maternal Plasma at Term</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/370c1704b4ece323031a1a7c2db86f53"><gtr:id>370c1704b4ece323031a1a7c2db86f53</gtr:id><gtr:otherNames>Gaccioli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6D1FFA0-836A-45BD-A782-6EA35C50A6D8"><gtr:id>C6D1FFA0-836A-45BD-A782-6EA35C50A6D8</gtr:id><gtr:title>Sex-Specific Differences in Human Placenta Transcriptome</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b261e3b7fd63ff5c4d7a58f8b5f637a"><gtr:id>1b261e3b7fd63ff5c4d7a58f8b5f637a</gtr:id><gtr:otherNames>Dopierala J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16AE9FE1-8853-419C-8A70-2BB2DE4C4BF6"><gtr:id>16AE9FE1-8853-419C-8A70-2BB2DE4C4BF6</gtr:id><gtr:title>Gender and Disease Specific Transcripts in the Placenta</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b59de5442428c378ad20358c60119aec"><gtr:id>b59de5442428c378ad20358c60119aec</gtr:id><gtr:otherNames>Dopierala, J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52857CE9-B6EA-4638-8EB5-64F743EF48D3"><gtr:id>52857CE9-B6EA-4638-8EB5-64F743EF48D3</gtr:id><gtr:title>46 Prediction of preeclampsia using the sFlt-1:PLGF ratio: A prospective cohort study of unselected nulliparous women</gtr:title><gtr:parentPublicationTitle>Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/adac6518578f2021c5823016d77e9f57"><gtr:id>adac6518578f2021c5823016d77e9f57</gtr:id><gtr:otherNames>Smith G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C075D73-A334-4DCA-99CD-64F6F235DA17"><gtr:id>4C075D73-A334-4DCA-99CD-64F6F235DA17</gtr:id><gtr:title>Meta-Analysis of Pre-Eclampsia Microarray Data</gtr:title><gtr:parentPublicationTitle>REPRODUCTIVE SCIENCES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/454fae3e3eaa914423cb8cb7ebb4bbaa"><gtr:id>454fae3e3eaa914423cb8cb7ebb4bbaa</gtr:id><gtr:otherNames>Dopierala Justyna A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1933-7191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B7489BD-52F1-4882-A055-B917D4DE6E30"><gtr:id>2B7489BD-52F1-4882-A055-B917D4DE6E30</gtr:id><gtr:title>Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/447b99a558c109ad4f3bfa9541e4af82"><gtr:id>447b99a558c109ad4f3bfa9541e4af82</gtr:id><gtr:otherNames>Sovio U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8521964-AE15-42C3-B17E-78514B8F15A0"><gtr:id>B8521964-AE15-42C3-B17E-78514B8F15A0</gtr:id><gtr:title>155: Screening for late fetal growth restriction using ultrasound and the sFlt-1:PlGF ratio</gtr:title><gtr:parentPublicationTitle>American Journal of Obstetrics and Gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/447b99a558c109ad4f3bfa9541e4af82"><gtr:id>447b99a558c109ad4f3bfa9541e4af82</gtr:id><gtr:otherNames>Sovio U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100221</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>